Everest Medicines’ Partner Calliditas Therapeutics Reports Positive Topline Results for Nefecon in Phase 3 Clinical Trial for Primary IgA Nephropathy
Everest Medicines' partner, Calliditas Therapeutics AB, has reported positive topline results from the global Phase 3 clinical trial of NefIgArd. The trial investigated the effects of Nefecon versus p ...